-
Founded in:
2012-04-17 -
Country:
China -
Address:
No. 1 Sibao Road, Xiantao City -
Tax NO.:
914290045942134679 -
Registered Funds:
48 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ketoconazole |
|
10mg | 65277-42-1 | 25 |
| Clobetasol propionate |
|
0.5mg | 25122-46-7 | 26 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Famotidine |
It has a significant inhibitory effect on gastric acid secretion and can also inhibit the secretion of pepsin
More
It has a significant inhibitory effect on gastric acid secretion and can also inhibit the secretion of pepsin |
76824-35-6 | 69 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Hydrocortisone-17-butyrate |
|
1mg | 13609-67-1 | 11 |
| PARAFFIN, LIQUID - REFERENCE SPECTRUM |
|
0 | ||
| Petrolatum |
|
8009-03-8 | 17 | |
| 1-Octadecanol |
|
112-92-5 | 8 | |
| Propylene glycol |
|
57-55-6 | 29 | |
| Glyceryl monostearate |
|
31566-31-1 | 13 | |
| Polyoxyethylene lauryl ether |
|
9002-92-0 | 0 | |
| Trisodium citrate dihydrate |
|
6132-04-3 | 30 | |
| tert-Butyl trioxide |
|
0 | ||
| Water |
|
7732-18-5 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.
More
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease. |
79902-63-9 | 63 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.
More
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease. |
79902-63-9 | 63 |